Voices desk
AstraZeneca Sinks After Reported $400 Billion Bristol Myers Merger Talks Surprise Investors
AstraZeneca shares fell sharply after reports emerged that the drugmaker had explored a potential merger with Bristol Myers Squibb. The reported talks stunned analysts, who questioned why one of pharma’s fastest-growing companies would pursue a deal that could become one of the industry’s largest ever.
3 min read
Continue reading